CYP2D6：修订间差异
删除的内容 添加的内容
无编辑摘要 |
无编辑摘要 |
||
| 第1行： | 第1行： | ||
{{PBB|geneid=1565}} |
{{PBB|geneid=1565}} |
||
'''细胞色素 P450 2D6（{{lang-en|Cytochrome P450 2D6}}）'''是一种由人类CYP2D6[[基因]][[编码]]的[[酶]]。CYP2D6主要-{zh-tw:作用;zh-cn:表達}-在[[肝脏]]，并且在[[中枢神经系统]]中 |
'''细胞色素 P450 2D6（{{lang-en|Cytochrome P450 2D6}}）'''是一种由人类CYP2D6[[基因]][[编码]]的[[酶]]。CYP2D6主要-{zh-tw:作用;zh-cn:表達}-在[[肝脏]]，并且也-{zh-tw:作用;zh-cn:表達}-在[[中枢神经系统]]中，包括[[黑质]]。 |
||
CYP2D6是[[细胞色素P450]]混合功能氧化酶系统的成员之一，是人体中最重要的代谢酶之一。CYP2D6参与25%的临床[[药物]]的代谢和清除，过程主要是O-[[去甲基化]]。<ref name="pmid19645588">{{cite journal | vauthors = Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF | title = New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme | journal = Drug Metab. Rev. | volume = 41 | issue = 4 | pages = 573–643 | year = 2009 | pmid = 19645588 | doi = 10.1080/03602530903118729 }}</ref>CYP2D6也参与多种内源性物质的代谢，如[[5-羟色胺]]和[[神经类固醇]]。<ref name="pmid19645588"/> |
CYP2D6是[[细胞色素P450]]混合功能氧化酶系统的成员之一，是人体中最重要的代谢酶之一。CYP2D6参与25%的临床[[药物]]的代谢和清除，过程主要是O-[[去甲基化]]。<ref name="pmid19645588">{{cite journal | vauthors = Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF | title = New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme | journal = Drug Metab. Rev. | volume = 41 | issue = 4 | pages = 573–643 | year = 2009 | pmid = 19645588 | doi = 10.1080/03602530903118729 }}</ref>CYP2D6也参与多种内源性物质的代谢，如[[5-羟色胺]]和[[神经类固醇]]。<ref name="pmid19645588"/> |
||
2017年4月17日 (一) 00:07的版本
细胞色素 P450 2D6（英語：Cytochrome P450 2D6）是一种由人类CYP2D6基因编码的酶。CYP2D6主要表達在肝脏，并且也表達在中枢神经系统中，包括黑质。
CYP2D6是细胞色素P450混合功能氧化酶系统的成员之一，是人体中最重要的代谢酶之一。CYP2D6参与25%的临床药物的代谢和清除，过程主要是O-去甲基化。[1]CYP2D6也参与多种内源性物质的代谢，如5-羟色胺和神经类固醇。[1]
引用
- ^ 1.0 1.1 Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev. 2009, 41 (4): 573–643. PMID 19645588. doi:10.1080/03602530903118729.
延伸閱讀
- Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998, 28 (12): 1129–65. PMID 9890157. doi:10.1080/004982598238868.
- Wolf CR, Smith G. Cytochrome P450 CYP2D6. IARC Sci. Publ. 1999, (148): 209–29. PMID 10493260.
- Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43 (1): 149–73. PMID 12171978. doi:10.1146/annurev.pharmtox.43.100901.140251.
- Lilienfeld S. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002, 8 (2): 159–76. PMID 12177686. doi:10.1111/j.1527-3458.2002.tb00221.x.
- Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 2004, 36 (2): 243–77. PMID 15237854. doi:10.1081/DMR-120034000.
- Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PD, Caldas C. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 2010, 12 (4): R64. PMC 2949659
. PMID 20731819. doi:10.1186/bcr2629. - Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Earl HM, Dunning AM, Pharoah PD, Caldas C. CYP2D6 gene variants and their association with breast cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 2011, 20 (6): 1255–8. PMID 21527579. doi:10.1158/1055-9965.EPI-11-0321.